StockData
TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Protara Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$2.33+0.01 (+0.43%)

Close on Oct 19, 2026

Market cap
$142.15M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 9, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 11, 2026Before market open–$-0.36–
Q1 FY2026
Ended Mar 31, 2026
May 13, 2026Before market open–––
Q4 FY2025
Ended Dec 31, 2025
Mar 10, 2026Before market open–––
Q3 FY2025
Ended Sep 30, 2025
Nov 10, 2025Before market open–$-0.31–
Q2 FY2025
Ended Jun 30, 2025
Aug 11, 2025Before market open–$-0.35–
Q1 FY2025
Ended Mar 31, 2025
May 8, 2025Before market open–$-0.29–
Q4 FY2024
Ended Dec 31, 2024
Mar 5, 2025Before market open–$-0.48–
Q3 FY2024
Ended Sep 30, 2024
Nov 12, 2024Before market open–$-0.50–
Q2 FY2024
Ended Jun 30, 2024
Aug 6, 2024Before market open–$-0.45–
Q1 FY2024
Ended Mar 31, 2024
May 2, 2024Before market open–$-0.97–
Q4 FY2023
Ended Dec 31, 2023
Mar 13, 2024Before market open–$-0.90–

Press releases

Announcements Protara Therapeutics filed with the SEC